Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Laurens — Clinton, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
- Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
- Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04227847
Sites in South Carolina: - Hollings Cancer Center — Charleston, South Carolina
- Medical University of South Carolina- Ashley River Tower — Charleston, South Carolina
- Medical University of South Carolina- Investigational Drug Services — Charleston, South Carolina
- Medical University of South Carolina- University Hospital — Charleston, South Carolina
Phase 1 Recruiting Academic/Other
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT02074839
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- McLeod Regional Medical Center — Florence, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Recruiting Network
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear …
Sponsor: Children's Oncology Group
NCT ID: NCT05702645
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina